SG10201504425SA - Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor - Google Patents
Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitorInfo
- Publication number
- SG10201504425SA SG10201504425SA SG10201504425SA SG10201504425SA SG10201504425SA SG 10201504425S A SG10201504425S A SG 10201504425SA SG 10201504425S A SG10201504425S A SG 10201504425SA SG 10201504425S A SG10201504425S A SG 10201504425SA SG 10201504425S A SG10201504425S A SG 10201504425SA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor
- methods
- unit dose
- dose formulations
- treating thrombosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87379206P | 2006-12-08 | 2006-12-08 | |
US94762907P | 2007-07-02 | 2007-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201504425SA true SG10201504425SA (en) | 2015-07-30 |
Family
ID=39110529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201504425SA SG10201504425SA (en) | 2006-12-08 | 2007-11-15 | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
Country Status (19)
Country | Link |
---|---|
US (1) | US8404724B2 (en) |
EP (1) | EP2101760B1 (en) |
KR (1) | KR101472765B1 (en) |
CN (1) | CN105193799A (en) |
AU (1) | AU2007333377B2 (en) |
CA (2) | CA2913963A1 (en) |
CO (1) | CO6220933A2 (en) |
CR (1) | CR10914A (en) |
EC (1) | ECSP099501A (en) |
ES (1) | ES2409090T3 (en) |
HK (1) | HK1134031A1 (en) |
IL (1) | IL199219A (en) |
MA (1) | MA31086B1 (en) |
NI (1) | NI200900145A (en) |
NZ (1) | NZ578180A (en) |
PT (1) | PT2101760E (en) |
RU (2) | RU2452484C2 (en) |
SG (1) | SG10201504425SA (en) |
WO (1) | WO2008073670A2 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1259485T3 (en) | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
AU2005257999B2 (en) | 2004-06-18 | 2011-12-08 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
DK1737889T3 (en) | 2004-10-19 | 2011-01-03 | Lonza Ag | Method for Solid-Phase Peptide Synthesis |
US8008303B2 (en) | 2005-09-16 | 2011-08-30 | Astrazeneca Ab | Biphenyl derivatives and their use in treating hepatitis C |
US20090186810A1 (en) * | 2006-03-27 | 2009-07-23 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
EA015942B1 (en) | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Substituted imidazoles, composition based thereon, a method for preventing or treating undesired thrombosis using thereof and method for inhibiting the coagulation of a blood sample |
ES2382055T3 (en) | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Methods for synthesizing pharmaceutical salts of a factor Xa inhibitor |
AU2008205093A1 (en) * | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
CN103071154A (en) | 2007-04-13 | 2013-05-01 | 千年药品公司 | Combination anticoagulant therapy with a compound that acts as a factor XA inhibitor |
MX2009011755A (en) * | 2007-05-02 | 2010-02-12 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor. |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
EP3241554B1 (en) | 2009-06-29 | 2020-01-29 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
JP6163304B2 (en) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Unit dose formulations of factor Xa inhibitor antidote and methods of use thereof |
WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2011084652A2 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
WO2011084519A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Methods of synthesizing factor xa inhibitors |
US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
EA015918B1 (en) * | 2010-03-03 | 2011-12-30 | Дмитрий Геннадьевич ТОВБИН | URETHANES, UREAS, AMIDES AND RELATED INHIBITORS OF Xa FACTORS |
TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
EP2655350B1 (en) | 2010-12-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
WO2012151451A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
EP2704720B1 (en) | 2011-05-03 | 2019-08-07 | Agios Pharmaceuticals, Inc. | Pyruvate kinase r activators for use in therapy |
CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
US20150224091A1 (en) * | 2011-08-31 | 2015-08-13 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
JP6529492B2 (en) | 2013-07-11 | 2019-06-12 | アジオス ファーマシューティカルズ, インコーポレイテッド | 2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutant Inhibitors for the Treatment of Cancer |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
WO2015054662A1 (en) | 2013-10-10 | 2015-04-16 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
GB201322777D0 (en) * | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
MA39726A (en) | 2014-03-14 | 2017-01-18 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
MA44392B1 (en) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | METHODS OF USING PYRUVATE KINASE ACTIVATORS |
WO2016205062A1 (en) * | 2015-06-15 | 2016-12-22 | Shifa Biomedical Corporation | Antithrombotic therapies |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
MA43000B1 (en) | 2015-10-15 | 2021-11-30 | Celgene Corp | Combination therapy for the treatment of malignant tumors |
FI3362065T3 (en) | 2015-10-15 | 2024-06-19 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
UY37806A (en) | 2017-07-11 | 2020-01-31 | Vertex Pharma | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS |
EA202090871A1 (en) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | INHIBITION OF UBIKVITIN-SPECIFIC PEPTIDASE 30 |
EA032764B1 (en) * | 2018-01-19 | 2019-07-31 | Общество С Ограниченной Ответственностью "Фармадиол" | NEW AMIDINES - Xa GROWTH FACTOR INHIBITORS |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
WO2019241793A1 (en) * | 2018-06-15 | 2019-12-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
CR20220316A (en) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
CN117794920A (en) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0813834B2 (en) * | 1990-08-01 | 1996-02-14 | 日東紡績株式会社 | Tripeptide derivative and proteolytic enzyme inhibitor containing the same as active ingredient |
GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
RU2194074C2 (en) * | 1994-02-14 | 2002-12-10 | Кирин Брюэри Компани, Лимитед | Polypeptide thrombopoietin (tpo), dna encoding polypeptide tpo (versions), method of preparing polypeptide (versions), pharmaceutical composition, method of treatment (versions), antibody against polypeptide tpo |
WO2000039118A1 (en) * | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Aromatic amides |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
DK1259485T3 (en) * | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
GB0021497D0 (en) * | 2000-09-01 | 2000-10-18 | Novartis Res Foundation | Compounds and their use |
US20040077690A1 (en) * | 2000-09-29 | 2004-04-22 | Bing-Yan Zhu | Quaternary amidino based inhibitors of factor xa |
US7598276B2 (en) * | 2005-11-08 | 2009-10-06 | Millenium Pharmaceuticals, Inc. | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
-
2007
- 2007-11-15 WO PCT/US2007/084887 patent/WO2008073670A2/en active Application Filing
- 2007-11-15 CA CA2913963A patent/CA2913963A1/en not_active Abandoned
- 2007-11-15 RU RU2009126147/15A patent/RU2452484C2/en not_active IP Right Cessation
- 2007-11-15 KR KR1020097014306A patent/KR101472765B1/en active IP Right Grant
- 2007-11-15 CA CA2671502A patent/CA2671502C/en not_active Expired - Fee Related
- 2007-11-15 SG SG10201504425SA patent/SG10201504425SA/en unknown
- 2007-11-15 CN CN201510530619.8A patent/CN105193799A/en active Pending
- 2007-11-15 NZ NZ578180A patent/NZ578180A/en not_active IP Right Cessation
- 2007-11-15 ES ES07864488T patent/ES2409090T3/en active Active
- 2007-11-15 AU AU2007333377A patent/AU2007333377B2/en not_active Ceased
- 2007-11-15 PT PT78644887T patent/PT2101760E/en unknown
- 2007-11-15 EP EP07864488A patent/EP2101760B1/en not_active Revoked
- 2007-12-07 US US11/999,957 patent/US8404724B2/en not_active Expired - Fee Related
-
2009
- 2009-06-07 IL IL199219A patent/IL199219A/en active IP Right Grant
- 2009-07-06 CR CR10914A patent/CR10914A/en unknown
- 2009-07-08 MA MA32076A patent/MA31086B1/en unknown
- 2009-07-08 CO CO09070741A patent/CO6220933A2/en not_active Application Discontinuation
- 2009-07-08 EC EC2009009501A patent/ECSP099501A/en unknown
- 2009-07-21 NI NI200900145A patent/NI200900145A/en unknown
-
2010
- 2010-02-08 HK HK10101405.5A patent/HK1134031A1/en not_active IP Right Cessation
-
2012
- 2012-02-10 RU RU2012104816/15A patent/RU2012104816A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008073670A3 (en) | 2008-11-27 |
CA2671502C (en) | 2017-01-24 |
RU2452484C2 (en) | 2012-06-10 |
NZ578180A (en) | 2012-02-24 |
ECSP099501A (en) | 2010-01-29 |
IL199219A0 (en) | 2010-03-28 |
CA2913963A1 (en) | 2008-06-19 |
MA31086B1 (en) | 2010-01-04 |
EP2101760B1 (en) | 2013-02-27 |
CO6220933A2 (en) | 2010-11-19 |
NI200900145A (en) | 2010-11-29 |
KR20090107499A (en) | 2009-10-13 |
CR10914A (en) | 2009-08-12 |
RU2009126147A (en) | 2011-01-20 |
EP2101760A2 (en) | 2009-09-23 |
KR101472765B1 (en) | 2014-12-15 |
PT2101760E (en) | 2013-05-07 |
RU2012104816A (en) | 2013-08-20 |
CN105193799A (en) | 2015-12-30 |
AU2007333377A1 (en) | 2008-06-19 |
WO2008073670A2 (en) | 2008-06-19 |
US20080153876A1 (en) | 2008-06-26 |
CA2671502A1 (en) | 2008-06-19 |
AU2007333377B2 (en) | 2014-01-16 |
US8404724B2 (en) | 2013-03-26 |
ES2409090T3 (en) | 2013-06-24 |
IL199219A (en) | 2013-10-31 |
HK1134031A1 (en) | 2010-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1134031A1 (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
HUS2000057I1 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
HRP20181971T1 (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor | |
IL202684A0 (en) | Anti-cd20 therapeutic compositions and methods of use thereof | |
EP2180873A4 (en) | Therapeutic dental composition and related methods | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
EP2021005A4 (en) | Methods and composition for treatment of inflammatory pain | |
IL206891A0 (en) | Therapeutic inhibitors of pai-1 function and methods of their use | |
SI2007895T1 (en) | Compositions and methods for therapy of cystic fibrosis | |
EP1720563A4 (en) | Methods and compositions for the treatment of inflammation | |
EP2124968A4 (en) | Compositions and methods for the treatment of muscle wasting | |
PL2012805T3 (en) | Therapeutic composition and use | |
EP2096927A4 (en) | Therapeutic compositions and methods of treatment with capsianoside-type compounds | |
EP2032151A4 (en) | Combination therapy method and formulation | |
EP2097085A4 (en) | Therapeutic materials and methods | |
ZA200904758B (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
GB0504657D0 (en) | Compositions and methods of treatment | |
EP2046109A4 (en) | Photosyntheticorganisms and compositions and methods of generating same | |
GB0609789D0 (en) | Treatment of inflammation | |
IL196588A0 (en) | Photosyntheticorganisms and compositions and methods of generating same | |
GB0614095D0 (en) | Medical treatments and compounds and compositions for use therein | |
GB0614097D0 (en) | Medical treatments and compounds and compositions for use therein | |
AU2007900995A0 (en) | Therapeutic Compositions and Methods of Treatment |